Acesso livre
Acesso livre

Infectologia Pediátrica

[Ainda não publicado] Pesquisadores afirmam que dose única de vacina contra HPV é altamente eficaz – “Resultado de estudo randomizado e controlado no Quênia traz novo ânimo para eliminar o câncer de colo de útero no mundo.”

22 Nov, 2021 | 09:23h

Single-dose HPV vaccine highly effective, researchers say – University of Washington School of Medicine

Conteúdos relacionados:

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

Editorial | Vacinas contra COVID-19 para crianças – “Embora seja verdade que a maioria das crianças tenham doença assintomática ou leve, algumas ficarão bastante doentes e um pequeno número irá a óbito. Este é o motivo de crianças serem vacinadas contra gripe, meningite, catapora e hepatite.”

19 Nov, 2021 | 13:17h

COVID-19 vaccines for children – Science

Conteúdo relacionado: Review: Should children under 12 years of age be vaccinated against COVID-19?

 

Comentário no Twitter

 

Revisão | Crianças com menos de 12 anos deveriam ser vacinadas contra COVID-19?

19 Nov, 2021 | 12:37h

Should children be vaccinated against COVID-19? – Archives of Disease in Childhood

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Covid: no Reino Unido, crianças só devem tomar a dose da vacina 12 semanas depois de uma infecção.

19 Nov, 2021 | 12:35h

Covid: Children told to delay jab for 12 weeks after infection – BBC

Relatório original: Joint Committee on Vaccination and Immunisation (JCVI) advice on COVID-19 vaccination in people aged 16 to 17 years: 15 November 2021

Mortes de crianças e jovens na Inglaterra após infecção por SARS-CoV-2 durante o 1º ano da pandemia – “Ao todo, 99,995% das crianças e jovens com teste positivo para SARS-CoV-2 sobreviveram.”

12 Nov, 2021 | 13:48h

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year – Nature

Conteúdo relacionado:

[Preprint] Study confirms children’s extremely low risk of death from Covid-19 – “99·995% of children and young people with a positive SARS-CoV-2 test survived”.

Study: Children and young people remain at low risk of COVID-19 mortality

 

Comentários no Twitter

 

OMS, CDC | Progresso global contra o sarampo fica ameaçado em meio à pandemia de COVID-19.

12 Nov, 2021 | 13:36h

Comunicado de imprensa: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization

Relatório: Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 – CDC Morbidity and Mortality Weekly Report

Comentário: Measles is a renewed global threat after 22 million babies missed their vaccines during the pandemic, CDC warns – CNN

 

Comentário no Twitter (fio – clique para saber mais)

 

Atualização sobre a síndrome inflamatória multissistêmica em crianças relacionada ao SARS-CoV-2.

11 Nov, 2021 | 16:17h

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Conteúdos relacionados:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Estudo randomizado | Vacina da Pfizer mostra 90,7% de eficácia na prevenção de Covid-19 em crianças de 5 a 11 anos de idade.

10 Nov, 2021 | 12:55h

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

 

Comentário no Twitter

 

[Ainda não publicado] Farmacêutica Sinovac afirma que sua vacina contra Covid-19 é segura para crianças e mesmo bebês a partir dos 6 meses de vida.

8 Nov, 2021 | 12:45h

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Conteúdos relacionados:

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Ponto de vista | Vacinas contra COVID-19 na pediatria: o que pais, médicos e formadores de políticas públicas precisam saber.

8 Nov, 2021 | 12:43h

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.